

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☒ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287  
Estimated average burden  
hours per response: 0.5

|                                                                        |                      |                       |                                                                         |  |  |                                                                                                                                                                                       |  |  |
|------------------------------------------------------------------------|----------------------|-----------------------|-------------------------------------------------------------------------|--|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| 1. Name and Address of Reporting Person*<br><b>Farrell, Michael J.</b> |                      |                       | 2. Issuer Name and Ticker or Trading Symbol<br><b>RESMED INC [RMD ]</b> |  |  | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)                                                                                                            |  |  |
| (Last)<br><b>RESMED INC.</b>                                           | (First)              | (Middle)              | 3. Date of Earliest Transaction (Month/Day/Year)<br><b>02/07/2025</b>   |  |  | Director<br><input checked="" type="checkbox"/> Officer (give title below)<br><b>10% Owner<br/>Other (specify below)<br/>Chief Executive Officer</b>                                  |  |  |
| (Street)<br><b>9001 SPECTRUM CENTER BLVD</b>                           |                      |                       | 4. If Amendment, Date of Original Filed (Month/Day/Year)                |  |  | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br>Form filed by More than One Reporting Person |  |  |
| (City)<br><b>SAN DIEGO</b>                                             | (State)<br><b>CA</b> | (Zip)<br><b>92123</b> |                                                                         |  |  |                                                                                                                                                                                       |  |  |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed Execution<br>Date, if any<br>(Month/Day/Year) | 3. Transaction<br>Code<br>(Instr. 8) |   | 4. Securities Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4, and 5) |                  |                | 5. Amount of Securities Beneficially<br>Owned Following Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership Form:<br>Direct(D) or Indirect (I)<br>(Instr. 4) | 7. Nature of Indirect<br>Beneficial Ownership<br>(Instr. 4) |
|---------------------------------|-----------------------------------------|----------------------------------------------------------|--------------------------------------|---|--------------------------------------------------------------------------|------------------|----------------|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|
|                                 |                                         |                                                          | Code                                 | V | Amount                                                                   | (A)<br>or<br>(D) | Price          |                                                                                                        |                                                               |                                                             |
| ResMed Common Stock             | 02/07/2025                              |                                                          | M (1)                                |   | 8,009                                                                    | A                | \$101.64       | 463,481                                                                                                | D                                                             |                                                             |
| ResMed Common Stock             | 02/07/2025                              |                                                          | S (1)                                |   | 8,009                                                                    | D                | \$236.772 (2 ) | 455,472                                                                                                | D                                                             |                                                             |
| ResMed Common Stock             |                                         |                                                          |                                      |   |                                                                          |                  |                | 0                                                                                                      | I                                                             | Lisette and Michael Farrell Foundation                      |
| ResMed Common Stock             |                                         |                                                          |                                      |   |                                                                          |                  |                | 2,090                                                                                                  | I                                                             | Lisette and Michael Farrell Family Trust                    |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr.3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4 and 5) |       | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                                     | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>Derivative<br>Securities<br>Beneficially Owned<br>Following Reported<br>Transaction(s)<br>(Instr. 4) | 10. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | 11. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|----------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|---|-------------------------------------------------------------------------------------------------------|-------|----------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                    |                                                                    |                                         |                                                             | Code                                 | V | (A)                                                                                                   | (D)   | Date<br>Exercisable                                            | Expiration<br>Date | Title                                                                                      | Amount<br>or<br>Number<br>of Shares |                                                     |                                                                                                                      |                                                                       |                                                                    |
| ResMed Common Stock Options                        | \$101.64                                                           | 02/07/2025                              |                                                             | M                                    |   |                                                                                                       | 8,009 | 11/11/2019 (3)                                                 | 11/14/2025         | ResMed Common Stock                                                                        | 8,009                               | \$0                                                 | 72,083                                                                                                               | D                                                                     |                                                                    |

Explanation of Responses:

- 1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
- 2. This transaction was executed in multiple trades at prices ranging from \$235.74 - \$238.67 The price reported above reflects the weighted average sale price.
- 3. Represents date options first become exercisable. Options vest 1/3 per year.

Michael J. Farrell, Chief Executive Officer  
\*\* Signature of Reporting Person

02/10/2025  
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.